Skip to main content

Catalyst Calendar

Mon, Oct 5, 2026

1 updates

7:00 AM

Insmed Announces CFO Transition

insmed.com

Mon, Sep 21, 2026

1 updates

7:00 AM

FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027

insmed.com

Wed, Sep 16, 2026

1 updates

7:00 AM

Insmed Expands Community Impact During Fifth Annual Global Day of Good

insmed.com

Fri, Sep 4, 2026

1 updates

7:00 AM

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

insmed.com

Thu, Sep 3, 2026

1 updates

7:00 AM

Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026

Presentation / Abstract • Phase 3ERS oral presentation Sun, Sep 6, 2026, 9:30 AM CESTinsmed.com

Wed, Aug 26, 2026

1 updates

7:00 AM

Insmed to Present at September 2026 Investor Conferences

insmed.com

Mon, Aug 24, 2026

1 updates

7:00 AM

BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

insmed.com